Five-year survival is similar in thyroid cancer patients with distant metastases prepared for radioactive iodine therapy with either thyroid hormone withdrawal or recombinant human TSH

Journal of Clinical Endocrinology and Metabolism

Volumn 96, Issue 7, 2011, Pages 2105-2111

  Tala, H ^a   Robbins, R ^b   Fagin, J A ^a   Larson, S M ^a   Tuttle, R Michael ^a  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b HOUSTON METHODIST HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

IODINE 131; LEVOTHYROXINE; RECOMBINANT THYROTROPIN;

ADULT; AGE; AGED; ARTICLE; BONE METASTASIS; CANCER SURVIVAL; DISTANT METASTASIS; FEMALE; FOLLOW UP; HUMAN; LUNG METASTASIS; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD REVIEW; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTIRELIN TEST; RADIOISOTOPE THERAPY; SURVIVAL RATE; THYROID CANCER;

ADULT; AGED; AGED, 80 AND OVER; CARCINOMA; FEMALE; HUMANS; IODINE RADIOISOTOPES; KAPLAN-MEIER ESTIMATE; MALE; MIDDLE AGED; NEOPLASM STAGING; RECOMBINANT PROTEINS; RETROSPECTIVE STUDIES; SURVIVAL RATE; THYROID NEOPLASMS; THYROTROPIN; TREATMENT OUTCOME;

EID: 79960081001     PISSN: 0021972X     EISSN: 19457197     Source Type: Journal    
DOI: 10.1210/jc.2011-0305     Document Type: Article

References (14)

1. Durante C, Haddy N, Baudin E, Leboulleux S, Hartl D, Travagli JP, Caillou B, Ricard M, Lumbroso JD, De Vathaire F, Schlumberger M 2006 Long-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapy. J Clin Endocrinol Metab 91:2892-2899 (Pubitemid 44271732)
2. Robbins RJ, Schlumberger MJ 2005 The evolving role of (131)I for the treatment of differentiated thyroid carcinoma. J Nucl Med 46(Suppl 1):28S-37S
3. Cooper DS, Doherty GM, Haugen BR, Haugen BR, Kloos RT, Lee SL, Mandel SJ, Mazzaferri EL, McIver B, Pacini F, Schlumberger M, Sherman SI, Steward DL, Tuttle RM 2009 Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 19:1167-1214
4. Pilli T, Brianzoni E, Capoccetti F, Castagna MG, Fattori S, Poggiu A, Rossi G, Ferretti F, Guarino E, Burroni L, Vattimo A, Cipri C, Pacini F 2007 A comparison of 1850 (50 mCi) and 3700 MBq (100 mCi) 131-iodine administered doses for recombinant thyrotropin-stimulated postoperative thyroid remnant ablation in differentiated thyroid cancer. J Clin Endocrinol Metab 92:3542-3546 (Pubitemid 47435333)
5. Tuttle RM, Lopez N, Leboeuf R, Minkowitz SM, Grewal R, Brokhin M, Omry G, Larson S 2010 Radioactive iodine administered for thyroid remnant ablation following recombinant human thyroid stimulating hormone preparation also has an important adjuvant therapy function. Thyroid 20:257-263
6. Hänscheid H, Lassmann M, Luster M, Thomas SR, Pacini F, Ceccarelli C, Ladenson PW, Wahl RL, Schlumberger M, Ricard M, Driedger A, Kloos RT, Sherman SI, Haugen BR, Carriere V, Corone C, Reiners C 2006 Iodine biokinetics and dosimetry in radioiodine therapy of thyroid cancer: procedures and results of a prospective international controlled study of ablation after rhTSH or hormone withdrawal. J Nucl Med 47:648-654 (Pubitemid 46768466)
7. Pötzi C, Moameni A, Karanikas G, Preitfellner J, Becherer A, Pirich C, and Dudczak R 2006 Comparison of iodine uptake in tumour and nontumour tissue under thyroid hormone deprivation and with recombinant human thyrotropin in thyroid cancer patients. Clin Endocrinol (Oxf) 65:519-523 (Pubitemid 44414277)
8. Freudenberg LS, Jentzen W, Petrich T, Frömke C, Marlowe RJ, Heusner T, Brandau W, Knapp WH, Bockisch A 2010 Lesion dose in differentiated thyroid carcinoma metastases after rhTSH or thyroid hormone withdrawal: (124)I PET/CT dosimetric comparisons. Eur J Nucl Med Mol Imaging 37:2267-2276
9. Robbins RJ, Driedger A, Magner J 2006 Recombinant human thyrotropin- assisted radioiodine therapy for patients with metastatic thyroid cancer who could not elevate endogenous thyrotropin or be withdrawn from thyroxine. Thyroid 16:1121-1130 (Pubitemid 44864487)
10. Robbins RJ, Larson SM, Sinha N, Shaha A, Divgi C, Pentlow KS, Ghossein R, Tuttle RM 2002 A retrospective review of the effectiveness of recombinant human TSH as a preparation for radioiodine thyroid remnant ablation. J Nucl Med 43:1482-1488 (Pubitemid 35285874)
11. Altekruse SF, KC, Krapcho M, Neyman N, Aminou R, Waldron W, Ruhl J, Howlader N, Tatalovich Z, Cho H, Mariotto A, Eisner MP, Lewis DR, Cronin K, Chen HS, Feuer EJ, Stinchcomb DG, Edwards BK, eds. Surveillance Epidemiology and End Results Cancer Statistics Review, 1975-2007. Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/1975-2007/, based on November 2009 SEER data submission, posted to the SEER web site, 2010
12. Hundahl SA, Fleming ID, Fremgen AM, Menck HR 1998 A National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985-1995. Cancer 83:2638-2648
13. Luster M, Lippi F, Jarzab B, Perros P, Lassmann M, Reiners C, Pacini F 2005 rhTSH-aided radioiodine ablation and treatment of differentiated thyroid carcinoma: a comprehensive review. Endocr Relat Cancer 12:49-64 (Pubitemid 40477087)
14. Tuttle RM, Brokhin M, Omry G, Martorella AJ, Larson SM, Grewal RK, Fleisher M, Robbins RJ 2008 Recombinant human TSH-assisted radioactive iodine remnant ablation achieves short-term clinical recurrence rates similar to those of traditional thyroid hormone withdrawal. J Nucl Med 49:764-770 (Pubitemid 351717542)